Full-Time
Clinical Scientist
Hyperfine
51-200 employees
Portable bedside MRI system for hospitals
No salary listed
No H1B Sponsorship
Palo Alto, CA, USA
Hybrid
Minimum 3 days on-site per week at Palo Alto, CA; up to 10% travel.
PhD
 Biology & Biotech (1) |
|---|
Get referred to Hyperfine
See people who can refer or advise you
- PhD or equivalent degree in biomedical engineering, neuroscience, imaging science, or related field
- 2–5+ years of experience in clinical research, imaging, or data science in industry setting
- Experience working with MRI data and imaging datasets required
- Applicants must be authorized to work for ANY employer in the United States; Hyperfine cannot sponsor now or in the future of any employment Visa
- Travel up to 10% of the time to customers, other Hyperfine offices, collaborators, conferences, etc.
- Support the design and execution of clinical studies aligned with Hyperfine strategic priorities
- Assist in defining study objectives, endpoints, and data strategies to support clinical evidence generation
- Partner with clinical sites to enable research protocols and optimize imaging workflows
- Support study startup activities, including IRB submissions and coordination with internal teams
- Monitor study progress, track milestones, and support execution of research service agreements (RSAs)
- Analyze clinical datasets and translate findings into publications, abstracts, and presentations
- Collaborate with clinical partners to develop manuscripts and support dissemination of scientific outputs
- Support engagement with external sitesand investigators as the MRI expert to align research efforts with company strategy
- Work cross-functionally with marketing, regulatory, legal, and imaging teams to support clinical and business objectives
- Contribute to partner-driven programs (e.g., externally funded collaborations) by tracking deliverables and identifying opportunities
- Hands-on experience with image processing, analysis tools (e.g., Python, MATLAB, or similar) preferred
- Experience contributing to clinical studies and publications preferred
Hyperfine creates medical imaging tools for hospitals, focusing on the Swoop system, the first FDA-cleared portable ultra-low field MRI that can image a patient’s brain at the bedside. How it works: a compact, portable MRI device is brought to the patient in settings like intensive care units, performing brain scans without moving the patient to a radiology suite. The open, safe design allows family members to stay nearby during imaging. Differentiation: it is already FDA-cleared and designed for point-of-care use, enabling bedside decision-making, faster treatment decisions, quicker discharges, and more efficient use of hospital staff and resources at a lower cost compared to traditional MRI workflows. Revenue model: Hyperfine sells the Swoop system and related services to hospitals, clinics, and other healthcare facilities. Goal: improve patient care by bringing diagnostic imaging directly to patients, increasing access to timely brain imaging and streamlining clinical workflows.
Company Size
51-200
Company Stage
IPO
Headquarters
Guilford, Connecticut
Founded
2014
Get referred to Hyperfine
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 45% to $3.9 million; 12 systems sold.
- Europe and the U.K. launched Model 2 in Q2 2026; first sales landed.
- Contrast PMR enrollment reached 75% in August 2026, targeting FDA submission by year-end.
What critics are saying
- March 18, 2026 Horizon loan charges 10.75% minimum interest and heavy covenants.
- Hyperfine filed S-3 for 1,083,335 warrant shares; dilution hits after 2026 draws.
- If contrast-label FDA submission slips past 2026, office revenue stalls and reimbursement stays constrained.
What makes Hyperfine unique
- Hyperfine owns the only FDA-cleared portable brain MRI, Swoop, in bedside settings.
- Model 2 adds Optive AI DWI; FDA cleared December 2025, CE/UKCA April 2026.
- AIIMS New Delhi and Yale PRIME validate differentiated point-of-care workflows in 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Hybrid Work Options
Wellness Program
Mental Health Support
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -3%2 year growth
↑ 1%Hyperfine reported second-quarter 2026 revenue of $3.9 million, up 45% year-over-year, marking its second-highest quarter ever. The medical imaging company sold 12 systems, a 50% increase from the prior year, with strong international contributions. Gross margin exceeded 50% for the fourth consecutive quarter, reaching 50.7%. The company posted a net loss of $9.3 million, though this included non-cash warrant liability losses. Cash burn improved 9% in the first half compared to the previous year. Hyperfine ended the quarter with $43.5 million in cash, extending its runway into 2028. The company is expanding internationally, achieving CE and UKCA approvals and entering India. It plans to submit for FDA contrast labelling approval by year-end, which could open new reimbursement opportunities. Management expects significant second-half revenue growth driven by hospital budget cycles, office placements, and new software releases.
Hyperfine has presented data showing its Swoop portable MRI system significantly reduces imaging wait times in emergency departments. The PRIME study, conducted at Yale School of Medicine with 100 patients, demonstrated a median time from imaging order to scan start of 1.28 hours with Swoop, compared to 7.76 hours with conventional MRI—a difference of 6.35 hours. FDA-cleared in 2020, the 1,400-pound wheeled Swoop system operates via tablet and requires no specialised MRI personnel. The device offers an alternative when fixed MRI machines are inaccessible, particularly for brain-related emergencies. The data was presented at the Society for Academic Emergency Medicine conference in May 2026. The announcement follows Hyperfine's $40 million loan facility from Horizon Technology in March 2026 to expand Swoop's reach across healthcare settings.
Hyperfine reported first-quarter revenue of $3.9 million, up 83% year over year, driven by adoption of its next-generation Swoop portable MRI system. The company sold 10 units in the quarter, with most being next-generation systems. Gross margin expanded to 50.7% from 41.3%, whilst net loss narrowed to $8.6 million. Hyperfine ended the quarter with $40.8 million in cash, supported by an initial $15 million debt tranche. The company reiterated full-year 2026 guidance for revenue of $20 million to $22 million and gross margin of 50% to 55%. Management highlighted pipeline strength in hospitals, neurology offices and international markets, plus progress towards a potential FDA submission for contrast-enhanced MRI use by end-2026.
Hyperfine Inc reported an 83% year-over-year revenue increase to $3.9 million for Q1 2026, with gross margins reaching 51% for the third consecutive quarter above 50%. The medical imaging company achieved CE and UKCA marks for its next-generation subsystem and advanced DWI Optiv AI software, enabling international expansion. Despite revenue growth, Hyperfine posted a net loss of $8.6 million and burnt through $8.8 million in cash during the quarter. The company maintains a cash position of $40.8 million, providing runway into 2028. Hyperfine's contrast PMR study enrollment has surpassed 50% of its target, supporting a potential FDA submission by end-2026. The company is focusing on larger medical offices and integrated delivery networks for its second-generation system deployments.
Hyperfine has introduced its Swoop portable MRI system at the All India Institute of Medical Sciences (AIIMS) in New Delhi, marking India's first deployment of bedside brain imaging technology for routine clinical use. The FDA-cleared, AI-powered system is now performing brain scans under Dr Shailesh Gaikwad's leadership at AIIMS's Centre for Neurological Conditions. The Swoop system addresses critical gaps in India's healthcare infrastructure by bringing MRI directly to patients' bedsides without requiring dedicated rooms, specialised power or patient transport. It supports neurological care across stroke units, trauma centres, intensive care units and neonatal wards. Radiosurgery Global serves as the exclusive distributor in India. The deployment establishes a foundation for clinical research, with AIIMS New Delhi positioned to generate real-world evidence for point-of-care brain imaging adoption across the country.